Targeting nuclear receptors for the treatment of fatty liver disease

N Tanaka, T Aoyama, S Kimura, FJ Gonzalez - Pharmacology & …, 2017 - Elsevier
Ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, were first …
被引用次数：227 相关文章

Targeting nuclear receptors for the treatment of fatty liver disease.

N Tanaka, T Aoyama, S Kimura… - Pharmacology & …, 2017 - europepmc.org
Ligand-activated nuclear receptors, including peroxisom e proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, w ere first …

[引用][C] Targeting nuclear receptors for the treatment of fatty liver disease

N Tanaka, T Aoyama, S Kimura… - Pharmacology & …, 2017 - cir.nii.ac.jp
[HTML] nih.gov

[HTML][HTML] Targeting nuclear receptors for the treatment of fatty liver disease

N Tanaka, T Aoyama, S Kimura… - Pharmacology & …, 2017 - ncbi.nlm.nih.gov
Ligand-activated nuclear receptors, including peroxisom e proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, w ere first …

Targeting nuclear receptors for the treatment of fatty liver disease

N Tanaka, T Aoyama, S Kimura… - Pharmacology & …, 2017 - pubmed.ncbi.nlm.nih.gov
Ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, were first …

Targeting nuclear receptors for the treatment of fatty liver disease.

N Tanaka, T Aoyama, S Kimura… - Pharmacology & …, 2017 - europepmc.org
Ligand-activated nuclear receptors, including peroxisom e proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, w ere first …